| __timestamp | Catalent, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 79383000 |
| Thursday, January 1, 2015 | 337300000 | 108402000 |
| Friday, January 1, 2016 | 358100000 | 46928000 |
| Sunday, January 1, 2017 | 402600000 | 74959000 |
| Monday, January 1, 2018 | 462600000 | 79716000 |
| Tuesday, January 1, 2019 | 512000000 | 74669000 |
| Wednesday, January 1, 2020 | 577900000 | 59040000 |
| Friday, January 1, 2021 | 687000000 | 77417000 |
| Saturday, January 1, 2022 | 844000000 | 91473000 |
| Sunday, January 1, 2023 | 831000000 | 94314000 |
| Monday, January 1, 2024 | 935000000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. Over the past decade, Catalent, Inc. has demonstrated a robust growth trajectory in its Selling, General, and Administrative (SG&A) expenses, increasing by approximately 180% from 2014 to 2024. This reflects the company's strategic investments in expanding its operational capabilities. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a modest increase of around 19% over the same period. This stability suggests a more conservative approach to cost management, possibly due to its niche focus in the biotech sector. Notably, the data for 2024 is incomplete for MannKind, indicating potential shifts in their financial strategy. As these companies navigate the complexities of the market, their SG&A trends offer valuable insights into their operational priorities and financial health.
Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights
Breaking Down SG&A Expenses: Sanofi vs MannKind Corporation
Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Summit Therapeutics Inc. or MannKind Corporation: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Catalent, Inc. and BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights